This exclusive report due out the week of August 22 will highlight the tremendous potential digital medicine has to influence healthcare and its unique role in reshaping the traditional roles of key players in the life science ecosystem. It will also examine the regulatory and operational challenges facing digital medicine stakeholders today as they work to deliver clinically impactful and economically viable digital medicine solutions in a saturated yet still-emerging business environment.
- Defining “digital medicine”—separating the toys from the tools
- The future of digital medicine’s regulatory environment, including issues in privacy and insights on current and future FDA practices
- Demonstration of digital medicine product value, economically and clinically
- Revealing the future of pharma’s strategy and new roles, partnership models emerging in digital medicine
This white paper will be available for download as a PDF in advance of Digital Medicine Connect 2016 held during BioPharm America™ on September 15, produced by EBD Group. The paper will cover comprehensive insights from a wide variety of industry leaders and reflect expert opinions, observations and predictions. The paper encompasses comprehensive insights from a wide variety of industry-leading groups such as Evidation Health, Hogan Lovells, StartUp Health, Validic, Pear Therapeutics, PureTech and more.
The themes covered in this paper are the focus of the Digital Medicine Connect (#DigitalMedicineConnect) program. Digital Medicine Connect is a one-day program that will examine the challenges facing digital medicine stakeholders as they work to deliver clinically impactful and economically viable digital medical solutions in a saturated yet still-emerging business environment. Register now.
Look for the white paper available on Insight the week of August 22.
About the Author
Editor-in-Chief, InsightFollow on Twitter More Content by Erin Righetti